Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A follow-on, Two-year Open-label Extension Study of Ganaxolone as add-on Therapy in Adult Patients With Drug-resistant Partial-onset Seizures

NCT02519439 is registered in ClinicalTrials.gov with Marinus Pharmaceuticals as lead sponsor.

NCT NCT02519439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02519439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A follow-on, Two-year Open-label Extension Study of Ganaxolone as add-on Therapy in Adult Patients With Drug-resistant Partial-onset Seizures
Lead sponsor
Marinus Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2015
Completion date
December 31, 2016
Enrollment
26 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

drug resistant partial onset seizure